RNA5SP162

Across TCGA pan-cancer cohorts, RNA5SP162 RNA is linked to patient survival in 13 of 34 cancer types, making it the most broadly survival-associated RNA5SP162 data layer.

The strongest signal is observed in cholangiocarcinoma (CHOL), where higher RNA5SP162 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated RNA5SP162 expression acts as an unfavorable survival marker, although some lineages such as CESC and COAD show a favorable association.

CHOL, PAAD, and LIHC are the cancer types where RNA5SP162 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CHOL	OS	Tertile	II,III,IV	0.089	0.712	.006	99	view →
PAAD	DFS	Tertile	All	0.098	0.505	.002	54	view →
LIHC	OS	Tertile	III,IV	0.051	0.738	<.001	36	view →
THCA	OS	Tertile	All	0.188	0.942	<.001	36	view →
KIRP	DFS	Tertile	All	0.676	0.927	<.001	33	view →
MESO	OS	Tertile	II,III,IV	0.246	0.569	.022	30	view →
LUSC	DFS	Tertile	III,IV	0.198	0.564	.011	27	view →
CESC	DFS	Tertile	All	0.918	0.513	.024	18	view →
SARC	DFS	Tertile	All	0.249	0.602	.019	12	view →
BLCA	DFS	Tertile	IV	0.213	0.483	.030	9	view →
PRAD	DFS	Tertile	All	0.806	0.937	.021	6	view →
SKCM	OS	Tertile	All	0.747	0.874	.048	3	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 13 lineages.

RNA5SP162–CHOL (OS)

Open the CHOL breakdown →